97 results about "MMP9" patented technology

Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.

The present invention is directed to methods and kits based, at least in part, on the identification of allele-specific responsiveness or non-responsiveness to glatiramer acetate for the treatment of autoimmune disorders, such as relapsing-remitting multiple sclerosis. The allele-specific responsiveness or non-responsiveness is based on polymorphisms in the following genes, CTSS, MBP, TCRB, CD95, CD86, IL-1R1, CD80, SCYA5, MMP9, MOG, SPP1 and IL-12RB2.

Emphysema and COPD are diagnosed, and the efficacy of therapeutic drug candidates for the treatment of emphysema and / or COPD is evaluated, by determining biomarkers selected from the group SpB, desmosine, VEGF, IGFBP2, MMP12, TIMP1, MMP9, Crabp2, Rbp1, Cyp26a1, Tgm2, Timp3, Adam17, Serpina1, Slpi, Col1a1, Eln, TGFβ1, TGFβ-RII, Sftpa1, Csf2, Cxcl1, Cxcl2, Cxcl5, IL-8Rβ, IL-8Rα, IL-6, TNF, EGF-R, Areg, PDGFα, HpGF, FGF7, Kdr, flt1, Angpt1, Tek, HIF1α, Hyou1, PGF, and tropoelastin.

The present invention relates to new proteins that bind to MMP9 and comprise at least one fragment of a heavy chain variable region and / or at least one fragment of a light chain variable region of an antibody. In particular, the MMP9 binding proteins according to the invention are able to neutralize MMP9 activity and are useful in the prevention and / or treatment of inflammatory and / or autoimmune diseases or cancers.In particular, the MMP9 binding proteins according to the invention are useful in diagnosis of MMP9-related disorders.

The invention relates to the technical field of biology, in particular to a set of biological markers and a relevant detection reagent kit. The invention provides the use of a combination of a substance for detecting Q346P mutation in a TEK gene or an active fragment thereof, a substance for detecting Q279R / R574P mutation in a MMP9 gene or an active fragment thereof, a substance for detecting Y1213Y mutation in a FLT1 gene or an active fragment thereof, and a substance for detecting X278X mutation in a TNFAIP6 gene or an active fragment thereof in a prepared reagent kit. The reagent kit is used for diagnosing vascular diseases and / or assessing the risk of the vascular diseases. The biological marker provided by the invention can avoid complete genome sequencing, so that needed sequencing data number can be greatly reduced, and the biological marker has excellent detection sensibility and specificity, and is low in cost, high in depth and accurate in detection on relevant mutation.

The invention discloses an osteosarcoma circulating tumor cell identification kit. The kit comprises capture probes for marker gene mRNAs and a signal amplification system. The marker genes comprise at least two epithelial cell marker genes selected from EpCAM, CDH1, KRT8, KRT16, KRT17, KRT18, KRT19 and KRT20 and at least two osteosarcoma metastasis-related interstitial cell marker genes selected from MMP2, MMP9, VIM, CDH2, FN1, HIF-1a, SERPINE1, SURVIVIN, TWIST1, AKT2 and SNAIL. The kit can completely detect osteosarcoma circulating tumor cells, evaluate their metastatic ability to avoid the possibility of the false negative result caused by different expression levels of CTCs in different types of cancers and further improve the accuracy of detection.

The invention provides a liver cancer metastasis prognosis quantitative antibody chip and a reagent kit. The quantitative prognosis chip comprises a substrate, specific antibodies, positive control and negative control. The specific antibodies of cancer related proteins are dispensed on the substrate. The liver cancer metastasis prognosis quantitative antibody is characterized in that the cancer related proteins include OPN (osteopontin), ICAM (intercellular cell adhesion moleculars), VEGF (vascular endothelial growth factors), MMP (matrix metal proteinase) 9, IL (interleukin) -8 and E-selectin. The reagent kit consists of the quantitative antibody chip adopting the OPN, the ICAM, the VEGF, the MMP9, the IL-8 and the E-selectin as detection objects, an antigen protein calibrator comprising OPN, ICAM, VEGF, MMP9, IL-8 and E-selectin and a biotinylated monoclonal detecting antibody comprising OPN, ICAM, VEGF, MMP9, IL-8 and E-selectin. The liver cancer metastasis prognosis quantitative antibody chip is successfully created, prognosis accuracy achieves 83% when the liver cancer metastasis prognosis quantitative antibody chip is applied to prognosis of liver cancer metastasis, and the liver cancer metastasis prognosis quantitative antibody chip and the reagent kit have an important clinical significance for judging prognosis of liver cancer patients.

The present invention relates to a method of detecting liver cancer in a mammalian subject by detecting an antibody in a test sample comprising a bodily fluid from the mammalian subject, wherein the antibody is an autoantibody immunologically specific for a tumour marker protein selected from the group consisting of MMP9, AIF1, EpCAM and CDKN1B, which method comprises contacting the test sample with a tumour marker antigen selected from the group consisting of MMP9, AIF1, EpCAM and CDKN1B and determining the presence or absence of complexes of the tumour marker antigen bound to autoantibodiespresent in the test sample where the presence of said complexes is indicative of the presence of liver cancer. Also included within the invention are corresponding methods of diagnosing and treating liver cancer in a mammalian subject, corresponding methods of predicting response to an anti-liver cancer treatment, a corresponding method of detecting an antibody in a test sample comprising a bodilyfluid from a mammalian subject and kits suitable for performing methods of the invention.

The invention discloses a suspension chip detection kit used for diagnosing preoperative ovarian cancer pelvic external transfer and a preparation method thereof. The kit mainly comprises three kinds of coupling hydroxyl fluorescent microspheres and three kinds of goat anti-human polyclonal antibodies, wherein the three kinds of coupling hydroxyl fluorescent microspheres respectively coat three kinds of murine anti-human monoclonal antibodies of full-length cDNA (complementary DNA) coding protein, i.e., MMP9 (matrix metalloproteinase-9), Hpa1 and CL; and the three kinds of goat anti-human polyclonal antibodies respectively are streptavidin and mycin-phycoerythrobilin affinity coupling MMP9, Hpa1 and CL goat anti-human polyclonal antibodies. The kit adopts a suspension chip technology to realize joint detection of the content of three kinds of extracellular matrix proteases MMP9, Hpa1 and CL. The kit can be used for diagnosing preoperative pelvic external transfer of ovarian cancer patients and contributes to determining the best therapeutic schedule and judging the prognosis condition and the like.